PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201000026CELUSYS 0026c mod#1 9 de-ob cancelling FUNDS — Elusys Therapeutics, Inc

Elusys Therapeutics, Inc holds $123.6M across 5 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 2 offers. Set-aside status: NONE. PoP ended Sep 30, 2018 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Elusys Therapeutics, Inc

Recipient

Sep 30, 2018

PoP end

$-499,207.77

Obligated

541711

NAICS

AN13

PSC

NONE

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Elusys Therapeutics, Inc — $90

Contract facts

NONE

Contract numberHHSO100201000026C

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentElusys Therapeutics, Inc

UEIELP1DCK8L191

NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN13

Place of performancePINE BROOK, NJ

PoP end (current)Sep 30, 2018

Obligated$-499,207.77

ELUSYS 0026C MOD#1 9 DE-OB CANCELLING FUNDS is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Elusys Therapeutics, Inc. Estimated value $138.3M ($-499,207.77 obligated). Current period of performance ends Sep 30, 2018. Last award drew 2 bidders. Place of performance: PINE BROOK, NJ.

ELUSYS 0026C MOD#1 9 DE-OB CANCELLING FUNDS

Recompete timing

Public

● Past PoP end (2891 days ago)

Current PoP ended Sep 30, 2018 (2891 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Elusys Therapeutics, Inc — $123.6M obligated across 5 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$123.6M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HHSO100201000026C?

HHSO100201000026C (ELUSYS 0026c mod#1 9 de-ob cancelling FUNDS) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $138.3M, currently held by Elusys Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HHSO100201000026C?

Barda - Aspr / Daappo / Barda Dcma awarded HHSO100201000026C to Elusys Therapeutics, Inc.

Who is the incumbent on HHSO100201000026C?

Elusys Therapeutics, Inc is the incumbent with $123.6M across 5 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2018.

When does Elusys Therapeutics, Inc’s HHSO100201000026C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2018. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on HHSO100201000026C — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Aug 22, 2024